Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 trial to assess homologous and heterologous boosting regimens in participants who received a primary series of a COVID-19 vaccine

Next Previous
Trial Profile

A Phase 1/2 trial to assess homologous and heterologous boosting regimens in participants who received a primary series of a COVID-19 vaccine

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 01 Apr 2022 New trial record
  • 25 Mar 2022 According to Novavax media release, Novavax is participating in this trial which is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) participants from this trial will be followed for 12 months, with topline results expected later this year and full results expected in 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top